A phase I/II study, the AlphaBet trial, evaluating the combination of 177Lu-PSMA-I&T and 223Ra to target PSMA-expressing cancer cells and bone metastasis in 36 mCRPC patients has recently been started in Australia (NCT05383079). This evidence concerns the gene FOLH1 and cancer.